Introduction
============

Members of the pregnancy specific glycoprotein family (PSGs) were first described in the early 1970s [@B1], [@B2]. In vitro, PSGs have been identified in cultured trophoblasts [@B3]. The human genome encodes for 11 PSGs [@B4], many of which undergo differential mRNA splicing, thus yielding a larger number of protein variants [@B5]. PSGs are mostly renowned for their abundant placental expression during pregnancy [@B2], which results in elevated PSG plasma levels. Below-average PSG plasma levels in pregnant women have been associated with "small for gestation age" (SGA) fetuses [@B6] and first-trimester maternal plasma levels of PSG1 have been shown to be influenced by smoking [@B7].

In contrast to members of the related, membrane-attached carcinoembryonic antigen (CEA) family, PSGs are secreted glycoproteins. Physiologically, PSGs are predominantly produced in syncytiotrophoblasts [@B8]. The PSG plasma level during pregnancy increases continuously until a plateau is reached around the 36th week of gestation [@B9], [@B10].

PSGs have been occasionally reported to be expressed in adenocarcinomas and have been discussed as putative onco-fetal biomarker for breast [@B11], [@B12] and lung cancer [@B13] [@B14], and for urothelial neoplasm [@B15]. Very recently, PSG expression has also been reported for squamous cell carcinomas and colorectal cancers [@B16].

PSG consist mostly of one immunoglobulin variable-like domain and two - three immunoglobulin constant-like domains [@B1], [@B2], [@B17]. In many cases, PSGs localize to the cell surface by interacting with further cell surface proteins. This includes binding of selected PSGs to members of the tetraspanin family, surface-expressed glycosaminoglycans, and various integrins (reviewed in [@B17])

PSGs are proposed to function as regulators of the innate and adaptive immune response [@B18]. Current data suggest that PSGs participate in modulating the adaptive T-cell response. PSGs are further suggested to interact with antigen presenting cells as well as influencing the spectrum of cytokines and chemokines secreted by monocytes and macrophages. In addition, a pro-angiogenic function of PSGs has been suggested as well as a role in regulating the activity and availability of transforming growth factor (TGF)-β1 and TGF-β2 [@B17].

Pancreatic cancer is the fourth most common internal cancer in men and women in Europe, with almost 80,000 deaths annually [@B19]. Taken worldwide, there is an annual incidence of over 200,000 pancreatic cancer cases with an annual mortality that is almost equal to the incidence rate [@B20]. Pancreatic cancer is an aggressive malignancy with one of the worst outcomes of all cancers and has a very poor prognosis: with a 1-year survival of less than 25%, and once the tumors have metastasized, a five-year survival of less than 5% [@B21]. Tumors evolve numerous mechanisms to escape from immune recognition [@B22]. Regulatory immune cells such as monocytes and neutrophils have been reported [@B23] to play a crucial role for PDAC immune escape and tumor aggressiveness. In the present study, we present one of the first analyses of PSG1 expression in a pancreatic cancer cohort.

Materials and Methods
=====================

Ethics statement
----------------

The study was approved by the Ethics Committee of the Medical University Freiburg, (13/11, "invasion and metastasis of periampullary cancers"). Before study inclusion, all patient data were pseudonymized.

Cell culture and transduction
-----------------------------

Colo-26 cells were provided by Prof. Zeiser, Freiburg, Germany. BxPC3 cells were purchased from ATCC. Cells were cultured in Dulbecco\'s modified eagle medium (DMEM; PAN Biotech) supplemented with 10 % fetal calf serum (FCS; PAN), 1 % non-essential amino acids, 1 % MEM vitamins, 1 % penicillin/streptomycin, and 10 mM HEPES (pH 7.5) at 37 °C in humidified air containing 5 % CO~2~. Serum-free cell-conditioned medium (CCM) of human BxPC3 pancreatic ductal adenocarcinoma cells for western-blot analysis (see below) was generated as described previously for the ovarian cancer cell line OV-MZ-6 [@B24]. Murine Colo-26 colon cancer cells were transduced for stable luciferase expression as described previously for 291PC Burkitt lymphoma cells [@B25]. These cells were further transduced with the vector pReceiver-Lv105, constitutively expressing untagged human PSG1 under control of the cytomegalovirus (CMV) promoter (Genecopoeia, EX-Z8117-Lv105). pReceiver-Lv105 lacking the PSG1 gene served as an empty vector control (Genecopoeia, EX-NEG-Lv105). Puromycin selection (20 μg/ml for 14 d) was used for selection of stable transfectants. Serum-free cell-conditioned medium (CCM) of human BxPC3 pancreatic ductal adenocarcinoma cells and Colo-26 cells for western-blot analysis (see below) was generated as described previously for the ovarian cancer cell line OV-MZ-6 [@B24].

Western Blot
------------

Cryopreserved tissues (normal pancreas, PDAC, placenta) were lysed in 10 mM Na-ethylenediaminetetraacetate, pH 8.0; 1 mM phenlymethansulfonylflouride; 1 μM trans-epoxysuccinyl-L-leucylamido(4-guanidino)butane using a Precellys homogenizer (ceramic beads 1.4 / 2.8 mm; 6500 rpm for up to four intervals of 2 min; Peqlab). Lysates were centrifuged for 10 min at 16600 x g, 4 °C. The supernatant was used for further analysis. Protein concentration was determined using the Bradford method (Bio-Rad). Samples (10 μg of protein) were separated by SDS-PAGE and transferred on polyvinylidene fluoride (PVDF) membrane using a semidry blotting system (BioRad), followed by blocking with 4 % non-fat milk in PBS-Tween and incubation with the primary mouse monoclonal antibody targeting human PSG1 (18 h at 4° C, 1:500, R&D Systems, MAB6799). After washing, the membranes were incubated for 18 h at 4° C with the corresponding secondary anti-mouse antibody (Dianova, Hamburg, Germany \#115-035-003). The membranes were washed and developed with the West Pico Chemiluminescent substrate (Pierce, Rockford, USA). Peroxidase activity was detected with the Fusion SL device (Peqlab, Erlangen, Germany). Deglycosylation was performed according to manufacturer\'s instructions ("Protein Deglycosylation Mix", New England Biolabs, Ipswich, MA, USA).

Patients and tumor tissue
-------------------------

All patients were treated between 2007 and 2011 at the Clinic for General and Visceral Surgery, University Medical Center Freiburg, Germany for PDAC. Histopathological work-up was performed at the Institute of Surgical Pathology, University Medical Center Freiburg, Germany. All histological samples from the tumor were revalidated independently by two experienced pathologists (P.B., H.F.). Clinical data from the database of the Clinic for General and Visceral Surgery, University Medical Center Freiburg, Germany were reviewed by S.K. and J.H. for correctness. In total, 104 patients were initially included.

Standard pathology work-up
--------------------------

From a prospectively maintained database, patients with PDAC were selected. For all specimens a standardized gross examination and histopathological work-up [@B26] was performed. Frozen section analysis, examined by experienced pathologists, was performed for all specimens at the Institute of Surgical Pathology, University Medical Center Freiburg, Germany. Tumor-masses were measured in all three dimensions; staging parameters (tumor size, tumor grade (G1 - G4), absence or presence of lymphatic (L0 / L1), blood vessel (V0 / V1), perineural invasion (Pn0 / Pn1) and local lymph node (N0 / N1) infiltration) were documented and classified according to the latest UICC classification. Tumor histology was grouped according to the latest WHO Classification. The parenchymal and deep resection margins, the oral and aboral duodenal resection margins as well as the resection margin of the Ductus choledochus were exanimated macro- and microscopically for the absence (R0) or presence (R1) of tumor cells.

PSG immunohistochemistry
------------------------

For immunohistochemical PSG analysis, from selected suitable formalin fixed and paraffin embedded tissue samples, slices of 2 µm thickness were prepared using the Leica RM2255 microtome. Antigen retrieval was performed for 30 minutes with DAKO Retrieval Solution S1699 in a Braun steamer and cooled down onto ice for 20 minutes afterwards. Next, incubation with PSG primary antibody ((PSG) Clone \# 684701 Catalog Number: MAB6799) for 30 minutes diluted 1:1000 in Zytomed dilution buffer (ZUC025-500) was conducted. Visualization was performed using DAKO detection system K5005. Sections were counterstained with haemalm for one minute, dehydrated in an ascending alcohol concentration and covered with xylol and coverslipping film (Tissue-Tek^R^ 4770).

*PSG evaluation:*Two experienced pathologists (HF, PB), blinded for clinico-pathological parameters, reviewed PSG expression according to the following protocol. Using 200-fold magnification, PSG expression was analyzed performing a semi-quantitative expression analyses by evaluating and multiplying PSG intensity (range 0 to 3) and the percentage of PSG-positive (range 0-100 %, intervals of 5%) tumor cells. In detail, if no signal was detectable the PSG expression was scored negative (Score 0). If a slack PSG signal was detectable score 1 (low intensity) was used. If PSG was expressed higher than score 1, but the haematoxylin counterstained nucleus demonstrated a higher staining intensity than PSG, score 2 (moderate intensity) was used. Score 3 (high intensity) was used if PSG intensity was higher than the haematoxylin counterstained nucleus. Furthermore, PSG localization "luminal and intracellular" and intracellular only was assessed. For all analyses, the percental predominant score was used for adjacent statistical analyses. Placental tissue was used as a positive control. Normal, non-malignant pancreatic tissue only demonstrates a very faint cytoplasmic expression of PSG in the exocrine cells.

*Statistical analysis:*IBM SPSS Statistics Version 21 (SPSS Inc. Chicago, IL) was used for statistical analyses. Survival data were analyzed using the Kaplan-Meier method and the Logrank test. Univariate analyses were performed via Spearman Chi squared test. For multivariate analyses, clinico-pathological predictors reaching a trend significance level (p\< 0.15) were included into a Cox proportional hazards model using forward and backward analyses. All statistical tests were performed two-sided. Significance level was set to p\<0.05.

Enzyme-linked Immunosorbent Assay (ELISA)
-----------------------------------------

ELISA for PSG1 concentration in EDTA-plasma samples was performed according to manufacturer\'s instructions (R&D Systems, Human PSG1 Quantikine ELISA Kit), based on a monoclonal antibody specific for human PSG1. EDTA-plasma of patients was collected preoperatively.

Murine Tumor Model
------------------

BALB/c mice were purchased from the local stock of the animal facility at Freiburg University Medical Center. Mice were used between 6 and 12 weeks of age. On day 0, 2.0 x 10^5^ luciferase expressing Colo-26 cells (see above) containing a human PSG1 overexpression vector (n = 3) or empty vector control (n = 3) were injected subcutaneously into the flanks of mice. Tumor volume was then monitored via bioluminescence imaging and palpation, with a weekly and alternating daily schedule, respectively. Maintenance of animal strains and work performed in this study was carried out in accordance with institutional guidelines and the German law for animal protection (Tierschutzgesetz) as published on May 18th 2006 with last amendment on July 28th 2014. Ethics approval registration number is G-13/116 RP regional council Freiburg.

Results and Discussion
======================

Public PDAC Expression Datasets Suggest a Weak Association Between Elevated PSG1 Expression and Shortened Survival
------------------------------------------------------------------------------------------------------------------

There have been a handful of reports on the expression of PSG proteins (sometimes also referred to as "Schwangerschaftsprotein" (SP), which has been used as a synonym) in epithelial cancers [@B11]-[@B13], [@B27]-[@B32]; however, PSG expression in PDAC has not yet been investigated. Based on these findings we explored publicly accessible PDAC gene expression datasets for a putative association between PSG1 mRNA expression and cumulative survival. Both the study of Stratford et al. [@B33] and Zhang et al. [@B34], probed using the Survexpress [@B35] and Precog [@B36] platforms, highlighted a trend for decreased survival in correlation with increased PSG1 expression (**Supplementary Figure [1](#SM1){ref-type="supplementary-material"}**). In both cases, the p-value (log-rank test) did not meet statistical significance (p = 0.27 and p = 0.11, respectively). However, since a similar trend was observed in two independent studies, we conclude that there is a weak association between elevated PSG1 expression and shortened survival.

Detection of PSG1 by Immunoblotting in PDAC Specimens
-----------------------------------------------------

In a next step, we used immunoblotting to probe for PSG1 expression in PDAC specimens. A commercially available, monoclonal antibody against human PSG1 detects a band at approximately 75 kDa, which is present in PDAC specimens and absent in normal pancreatic tissue (**Figure [1](#F1){ref-type="fig"}**). The same band was detected in placenta tissue and conditioned medium of human BxPC3 PDAC cells (**Figure [1](#F1){ref-type="fig"}**). The ∼ 75 kDa band is absent in conditioned medium of wild-type murine Colo-26 cells but overexpression of human PSG1 leads to its appearance. Since PSG1 is reported to be glycosylated and the detected molecular weight of ∼ 75 kDa exceeds the ∼ 380 residue length of mature PSG1, we also probed for deglycosylated PSG1. Upon deglycosylation, the molecular weight shifts to approximately 37 kDa, in line with the ∼ 380 residue length of mature PSG1.

PSG proteins belong to the carcinoembryonic antigen (CEA) family [@B17]. Carcinoembryonic antigen-related cell adhesion molecule (CEACAM)-5 is the prototypic member of the CEA family. Elevated expression of CEACAM5 in solid tumors has been reported as early as 1965 [@B37] and CEACAM5 plasma levels are nowadays used for the diagnostic monitoring of several cancers, including PDAC [@B38], [@B39]. CEACAM5 is typically detected with a molecular weight \> 150 kDa by immunoblotting [@B39]. In our PDAC samples, we detect PSG1 at approximately 75 kDa.

However, some members of CEACAM family have been detected in the molecular weight range around 70 KDa, e.g. CEACAM6 [@B40]. With regard to putative antigen cross-reactivity with CEACAMs, it is worth noting that we detect a single strong band in western-blot analysis, and not multiple strong bands, e.g. stemming from cross-reactivity with multiple CEACAM proteins. Regarding CEACAM6, its mature form consists of less than 290 residues with extensive glycosylation yielding a 64 kDa products. In our study, deglycosylation yields a ∼ 37 kDa product, which is too large for a \< 290 residue protein. The differences in molecular weight further support detection of PSG1. Nevertheless, as for any antibody-based method, we acknowledge a vague and generally applicable possibility of antigen cross-reactivity.

Furthermore, two global transcriptome studies comparing PDAC with non-malignant pancreatic tissue corroborate our finding of increased PSG1 expression PDAC. The studies of Logsdon et al [@B41] and Iacobuzio-Donahue et al [@B42] both report significantly elevated PSG1 transcript levels in PDAC (p \< 0.01, two-tailed student t-test).

In summary, our immunoblotting data supports tumor-associated expression of PSG1 in PDAC.

Immunohistochemical Analysis of PSG1 Expression in PDAC
-------------------------------------------------------

*Baseline parameters:*Next we analyzed the impact of PSG expression levels and cellular localization on overall survival in a cohort of 104 adjuvant-treated PDAC patients. Median age was 66 years, 54 patients were female, 50 patients\' male. 90 patients received a pylorus preserving pancreaticoduodenotomie (PPPD), 13 a Whipple operation and one patient a total pancreatectomy. Median tumor size was 28 mm (range 3 - 60 mm). According to UICC-Classification four patients were classified as T1 (4/104; 3.8%), six T2 (6 / 104; 5.8 %), 88 T3 (88 / 104; 84.6 %) and six T4 (6 / 104; 5.8 %). Lymph node status was assessed for all patients. Thereby 27 patients (26 %) were nodal negative (N0), 77 (74 %) were nodal positive. Lymphangioinvasion (L1) was observed in 51 (49 %), haemangioinvasion (L1) in 20 (19 %), perineuralinvasion (Pn1) in 79 (76 %) and distant metastases (M1) in 3 (3 %) patients. Regarding tumor differentiation, three tumors were well (3 / 104; 2.9 %), 58 moderately (58 / 104; 55.8 %), 42 poorly (42 / 104; 40.4 %) and one un-differentiated (1 / 104; 1 %). One resection margin (1 / 104; 1 %) was macroscopically, 36 resection margins (36 / 104; 34.6%) were microscopically positive and 67 resection margins (67/104; 64.4%) were microscopically negative for tumor cells.

PSG1 immunohistochemistry
-------------------------

PSG1 expression was analyzed in all 104 PDAC samples. To this end, PSG1 expression was probed by immunohistochemistry as detailed in Materials and Methods. As a positive control, we initially probed placenta tissue and detected prototypical luminal PSG1 staining, which was predominantly restricted to luminally located syncytiotrophoblasts (**Figure [2](#F2){ref-type="fig"}a**). In line with the immunoblotting analysis, normal, non-malignant pancreatic tissue only demonstrates a very faint cytoplasmic expression of PSG in the exocrine cells. (**Figure [2](#F2){ref-type="fig"}b**). However, in all PDAC specimens some PSG1 staining was detected with no case of completely negative staining. 22 tumors demonstrated weak (22 / 104; 21.15 %), 17 (17/ 104; 16.35 %) a moderate and 65 (65/ 104; 62.5 %) a strong staining intensity. PSG1 was expressed as a percentage range from 1 to 100 % (mean = 77.56 %). Importantly, two types of staining were distinguished, based on the subcellular localization of intense PSG1 staining:

a\) predominantly apical and partially cytoplasmic (prototypical cases shown in **Figure [2](#F2){ref-type="fig"}c - e)**, referred to as "apical-cytoplasmic"

b\) predominantly cytoplasmic (prototypical cases shown in **Figure [2](#F2){ref-type="fig"}f - h**), referred to as "cytoplasmic-only"

31 % (32 / 104) of all tumors were "cytoplasmic-only" PSG1 positive, whereas 69 % (72 / 104) of all tumors were "apical-cytoplasmic "PSG1 positive. Several earlier publications have already demonstrated a seemingly intracellular / cytoplasmic staining for PSG proteins in adenocarcinoma specimens [@B11], [@B28], [@B29] and normal syncytiotrophoblast cells [@B8], [@B43]. Differential subcellular localization in a disease setting has been previously reported for other proteins such as the cell surface protease prostasin in dermatitis [@B44].

Statistical analyses
--------------------

Univariate analyses of our cohort highlighted metastatic lymph node ratio and surgical regime (pylorus preserving pancreatoduodenectomy vs. Whipple procedure vs. pancreatectomy) as significant, classical, clinico-pathological parameters for survival (p=0.022). This is in line with a previous report [@B45]. Statistical trends (p ≥ 0.05 and \< 0.15) were observed for perineural invasion (p=0.116) and tumor grading (p=0.107). Classical UICC relevant parameters (TNM classification, lymphangiosis, haemangiosis) as well as patients\` gender or age and R-classification demonstrated no significant correlation in univariate analyses. Considering PSG expression in the tumor cells, neither PSG intensity nor percentage correlated with overall survival (p= 0.0.744 and p=0.319). However, "cytoplasmic-only" versus "apical-cytoplasmic" PSG1 expression (p \< 0.001) was highly significant in univariate analyses (**Figure [3](#F3){ref-type="fig"}**) with "cytoplasmic-only" staining being linked to shorter cumulative survival. Details of the univariate analysis are shown in **Table [1](#T1){ref-type="table"}**.

In a second step, we included all univariate correlations with p \< 0.15 for a Cox proportional hazards model calculation performing forward selection and backward elimination. This multivariate analysis corroborated "intracellular-only" versus "apical-cytoplasmic" PSG expression and lymph node ratio (p = 0.01) as independent predictors of survival after resection.

PSG1 ELISA
----------

We further probed PSG1 levels in plasma of healthy, pregnant (n = 2, for control purposes only) and non-pregnant individuals (n = 3) as well as PDAC patients (n = 8) using a commercially available PSG1 ELISA. In the non-pregnant individuals and PDAC patients we detected PSG1 concentrations in the range of 0.0 - 1.2 ng / ml (**Figure [4](#F4){ref-type="fig"}**); in line with an earlier report [@B11]. We did not detect elevated plasma levels of PSG1 in PDAC patients compared to healthy, non-pregnant controls. This finding is also in line with an earlier report [@B11].

### PSG1 Expression Does Not Affect Tumor Growth in an Immunocompetent Murine Model System

Furthermore, we attempted to probe the effect of PSG1 expression on tumor growth using an immunocompetent model system. To this end, we used murine Colo-26 cancer cells, which were injected subcutaneously into the flanks of immunocompetent BALB/c mice. Stable expression of human PSG1 was achieved by transducing Colo-26 cancer cells with an expression vector for human PSG1. The same expression vector, lacking the PSG1 gene served as the "empty vector" control. Usage of a highly efficient viral transduction system together with antibiotic selection ensured the generation of stable transfectants. Expression or absence of human PSG1 is shown in **Figure [1](#F1){ref-type="fig"}**. 2.0 x 10^5^ Colo-26 cells were injected subcutaneously into the flanks of BALB/c mice. Tumor growth was monitored by palpation (**Figure [5](#F5){ref-type="fig"}a**) or bioluminescence (**Figure [5](#F5){ref-type="fig"}b**). In both cases, an impact of PSG1 expression on tumor growth was not detected. To our knowledge, this is one of the first *in vivo* studies focusing on the tumor-contextual function of a PSG protein.

Conclusion
==========

We present the first immunohistochemical analysis of PSG1 expression in PDAC. Our findings show "cytoplasmic-only" presence of PSG1 (as opposed to "apical-cytoplasmic") is associated with shorter cumulative survival after resection. At the same time, we did not detect elevated PSG1 levels in the plasma of PDAC patients nor did PSG1 expression affect tumor growth in an immunocompetent murine model system. In combination, these results underline that the role of the PSG system in PDAC biology warrants further investigation.

Supplementary Material {#SM0}
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![Immunoblot detection of PSG1 using a commercially available monoclonal antibody. In two cases, a strong signal between 75 and 100 kDa is observed in samples from pancreatic adenocarcinoma (PDAC), which is missing in non-malignant pancreatic tissue. Deglycosylation yields a signal of approximately 37 kDa. Immunoblot detection of PSG1 in placenta tissue equally yielded a strong signal at 75 kDa, which was also detected in conditioned medium of cultured BxPC3 PDAC cells and in murine Colo-26 cells that were stably transfected to produce human PSG1.](jcav07p2018g001){#F1}

![Immunohistochemical analysis of PSG1. Representative pictures are shown. (a) In placenta tissue, a prototypical luminal PSG1 localization is detected. (b) Normal, non-malignant pancreatic tissue only demonstrates a faint cytoplasmic expression of PSG in the exocrine cells. In PDAC tissue, substantial PSG1 levels are detected, with two types of distinct subcellular localizations: (c - e) predominantly apical (black arrow) and (f - h) predominantly cytoplasmic (green arrows); each at low (c, f), moderate (d, g), and high (e, h) PSG1 expression. (c - h) were recorded at 400 fold magnification.](jcav07p2018g002){#F2}

![Kaplan-Meier plot depicting overall survival of PDAC patients (n = 104) according to PSG1 localization ("cytoplasmic and apical" in green or "cytoplasmic only" in blue). "Cytoplasmic only" localization correlated to shorter overall survival (log-rank p-value \< 0.001).](jcav07p2018g003){#F3}

![ELISA detection of PSG1 in plasma samples of healthy, pregnant and non-pregnant individuals and eight PDAC patients. n.d., not detected.](jcav07p2018g004){#F4}

![Tumor growth of Colo-26 cells expressing human PSG1 or corresponding Colo-26 control cells, subcutaneously injected into the flanks of immunocompetent BALB/c mice (n =3, each). Tumor growth was monitored by **(a)** palpation or **(b)** bioluminescence.](jcav07p2018g005){#F5}

###### 

Univariate and multivariate survival analysis.

  -----------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                Condition            N     Events (deaths)   Median survival (months)   Logrank\      Hazard Ratio\        Cox\
                                                                                                   p             (95% CI)             p
  ------------------------ -------------------- ----- ----------------- -------------------------- ------------- -------------------- -----------
  All patients                                  104   59                19                                                            

  Gender                   male                 50    29                18                         0.869         **NI**               

  female                   54                   30    19                                                                              

  Age ^1^                  \< 67                55    31                20                         0.532         **NI**               

  \>= 67                   49                   28    17                                                                              

  Neoadjuvant therapy      no\                  95\   52\               19\                        0.250         **NI**               
                           yes                  9     7                 17                                                            

                                                                                                                                      

  Resection                PPPD                 90    52                19                         **\<0.001**                        E.

  Whipple                  13                   6     24                                                                              

  total PE                 1                    1     2                                                                               

  Tumor size (mm)          \< 25                36    23                19                         0.534         **NI**               

  \>= 25                   64                   33    20                                                                              

  pT Stage                 pT1/2                10    7                 20                         0.740         **NI**               

  pT3/4                    94                   52    19                                                                              

  pN Stage                 pN0                  26    13                19                         0.881         **NI**               

  pN1                      78                   46    18                                                                              

  Lymph node ratio         \< 0.106             52    27                25                         **0.022**     **0.271 - 6.653**    **0.010**

  \>= 0.106                52                   32    17                                                                              

  Lymphangiosis            L0                   53    35                19                         0.930         **NI**               

  L1                       51                   24    18                                                                              

  Hemangiosis              V0                   84    45                20                         0.202         **NI**               

  V1                       20                   14    12                                                                              

  Perineural invasion      Pn0                  25    19                14                         **0.116**                          **E**

  Pn1                      79                   40    20                                                                              

  Grade                    G1/2                 61    35                20                         **0.107**                          **E**

  G3/4                     43                   24    14                                                                              

  Resection Margin         R0                   67    35                18                         0.175         **NI**               

  R+                       37                   24    19                                                                              

  Distant metastasis       M0                   101   53                19                         0.158         **NI**               

  M1                       3                    3     6                                                                               

  PSG intensity            Weak                 22    14                25                         0.744         **NI**               

  Moderate                 17                   8     19                                                                              

  Strong                   65                   37    16                                                                              

  PSG percent              \< 80 %              66    34                32                         0.319         **NI**               

  \>=80 %                  36                   25    13                                                                              

  PSG localisation         Solely cytoplasmic   32    25                11                         **\<0.001**   **0.094 - 12.583**   **0.001**

  Apical and cytoplasmic   72                   34    25                                                                              
  -----------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CI 95% confidence interval, NI not included, E eliminated from Cox proportional hazards model in stepwise backward elimination, PPPD pylorus preserving pancreatoduodenectomy, Whipple classical Whipple procedure, PE pancreatectomy, PSG pregnancy specific β-1 glycoprotein.
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